Pyxis Oncology Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
56
- Stock Symbol
-
PYXS
- Investments
-
2
- Share Price
-
$1.81
- (As of Friday Closing)
Pyxis Oncology General Information
Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Contact Information
Website
www.pyxisoncology.comCorporate Office
- 321 Harrison Avenue
- 11th Floor, Suite 1
- Boston, MA 02118
- United States
Corporate Office
- 321 Harrison Avenue
- 11th Floor, Suite 1
- Boston, MA 02118
- United States
Pyxis Oncology Timeline
Pyxis Oncology Stock Performance
As of 20-Nov-2026, Pyxis Oncology’s stock price is $1.81. Its current market cap is $216M with 120M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.81 | $1.68 | $1.03 - $5.55 | $216M | 120M | 1.06M | -$1.27 |
Pyxis Oncology Financials Summary
As of 30-Sep-2026, Pyxis Oncology has a trailing 12-month revenue of $11M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 179,177 | 14,421 | (31,511) | (31,568) |
| Revenue | 11,038 | 13,858 | 16,146 | 0 |
| EBITDA | (83,500) | (77,334) | (83,552) | (78,493) |
| Net Income | (86,708) | (79,621) | (77,331) | (73,790) |
| Total Assets | 76,770 | 91,520 | 157,181 | 173,726 |
| Total Debt | 17,400 | 18,673 | 20,200 | 21,331 |
Pyxis Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pyxis Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pyxis Oncology Comparisons
Industry
Financing
Details
Pyxis Oncology Competitors (51)
One of Pyxis Oncology’s 51 competitors is Akari Therapeutics, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akari Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Nascent Biotech | Corporation | San Diego, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Immunophotonics | Private Equity-Backed | Saint Louis, MO | ||||
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA |
Pyxis Oncology Patents
Pyxis Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226947-A1 | Constructs, compositions, and methods for treating pd(l)1 resistant diseases and disorders | Pending | 24-Apr-2025 | ||
| WO-2026112135-A1 | Constructs, compositions, and methods for treating diseases and disorders expressing extra domain b splice variant of fibronectin | Pending | 19-Nov-2024 | ||
| AU-2025247255-A1 | Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders | Pending | 29-Mar-2024 | ||
| WO-2025208105-A1 | Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders | Pending | 29-Mar-2024 | ||
| AU-2024312447-A1 | Anti-klrg1 antibodies and uses thereof | Pending | 23-Jun-2023 | C07K16/2851 |
Pyxis Oncology Signals
Pyxis Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pyxis Oncology Investments & Acquisitions (2)
Pyxis Oncology’s most recent deal was a Merger/Acquisition with Apexigen for . The deal was made on 23-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Apexigen | 23-Aug-2023 | Merger/Acquisition | Drug Discovery | ||
| Kyma Therapeutics | 25-May-2021 | Joint Venture | Drug Discovery |
Pyxis Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Pyxis Oncology FAQs
-
When was Pyxis Oncology founded?
Pyxis Oncology was founded in 2018.
-
Where is Pyxis Oncology headquartered?
Pyxis Oncology is headquartered in Boston, MA.
-
What is the size of Pyxis Oncology?
Pyxis Oncology has 56 total employees.
-
What industry is Pyxis Oncology in?
Pyxis Oncology’s primary industry is Drug Discovery.
-
Is Pyxis Oncology a private or public company?
Pyxis Oncology is a Public company.
-
What is Pyxis Oncology’s stock symbol?
The ticker symbol for Pyxis Oncology is PYXS.
-
What is the current stock price of Pyxis Oncology?
As of 20-Nov-2026 the stock price of Pyxis Oncology is $1.81.
-
What is the current market cap of Pyxis Oncology?
The current market capitalization of Pyxis Oncology is $216M.
-
What is Pyxis Oncology’s current revenue?
The trailing twelve month revenue for Pyxis Oncology is $11M.
-
Who are Pyxis Oncology’s competitors?
Akari Therapeutics, Nascent Biotech, Kite Pharma, Immunophotonics, and ORIC Pharmaceuticals are some of the 51 competitors of Pyxis Oncology.
-
What is Pyxis Oncology’s annual earnings per share (EPS)?
Pyxis Oncology’s EPS for 12 months was -$1.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process